SancusoActive Ingredient(s): Granisetron
FDA Approved: * September 12, 2008
Pharm Company: * STRAKAN INTL
Granisetron is a serotonin 5-HT3 receptor antagonist used as an antiemetic to treat nausea and vomiting following chemotherapy and radiotherapy. Its main effect is to reduce the activity of the vagus nerve, which is a nerve that activates the vomiting center in the medulla oblongata. It does not have much effect on vomiting due to motion sickness. This drug does not have any effect on dopamine receptors or muscarinic receptors. Granisetron was developed by chemists working at the British dr... [wikipedia]* May have multiple approval dates, manufacturers, or labelers.
Sancuso 3.1 mg/24h Transdermal PatchNDC: 42747-726
Sancuso 3.1 mg/24h Transdermal PatchNDC: 54868-5985
Physicians Total Care, Inc.